Jones, A.B.; Tuy, K.; Hawkins, C.C.; Quinn, C.H.; Saad, J.; Gary, S.E.; Beierle, E.A.; Ding, L.; Rochlin, K.M.; Lamb, L.S.;
et al. Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Cancers 2024, 16, 2852.
https://doi.org/10.3390/cancers16162852
AMA Style
Jones AB, Tuy K, Hawkins CC, Quinn CH, Saad J, Gary SE, Beierle EA, Ding L, Rochlin KM, Lamb LS,
et al. Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Cancers. 2024; 16(16):2852.
https://doi.org/10.3390/cancers16162852
Chicago/Turabian Style
Jones, Amber B., Kaysaw Tuy, Cyntanna C. Hawkins, Colin H. Quinn, Joelle Saad, Sam E. Gary, Elizabeth A. Beierle, Lei Ding, Kate M. Rochlin, Lawrence S. Lamb,
and et al. 2024. "Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma" Cancers 16, no. 16: 2852.
https://doi.org/10.3390/cancers16162852
APA Style
Jones, A. B., Tuy, K., Hawkins, C. C., Quinn, C. H., Saad, J., Gary, S. E., Beierle, E. A., Ding, L., Rochlin, K. M., Lamb, L. S., & Hjelmeland, A. B.
(2024). Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Cancers, 16(16), 2852.
https://doi.org/10.3390/cancers16162852
